Genetic heterogeneity in AML: the reasoning behind targeting FLT3 and IDH
Researchers and clinicians now recognize that AML comprises a multitude of subtypes. In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses our current unders...
Author: VJHemOnc
Added: 01/17/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts